The Food and Drug Administration Monday authorized the emergency use of two new products designed to respond to the COVID-19 ventilator shortage. FDA approved the NASA’s second VITAL ventilator.

Like NASA’s first iteration of the device, VITAL is designed to last three-to-four months using components sourced from outside the current medical device supply chain. Unlike NASA’s first ventilator, VITAL uses an internal compressor as its energy source, rather than wall gas.

Meanwhile, the Fitbit Flow earned an FDA emergency use authorization as an emergency resuscitator. The Fitbit Flow is a continuous respiratory support system that includes an FDA-cleared, Ambu-designed manual resuscitator bag with audible and visual alarms.

By pairing the actuator with a manual resuscitator, health care professionals can use the device to support patients’ respiratory needs when no FDA-cleared clinical ventilators are available.

Related News Articles

Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…